Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
CAPR Stock Chart & Stats
$27.93
-$0.36(-2.53%)
At close: 4:00 PM EST
$27.93
-$0.36(-2.53%)
Day’s Range― - ―
52-Week Range$4.30 - $40.37
Previous CloseN/A
Volume187.65K
Average Volume (3M)1.05M
Market Cap
$1.52B
Enterprise Value$1.27B
Total Cash (Recent Filing)$98.57M
Total Debt (Recent Filing)$14.54M
Price to Earnings (P/E)―
Beta2.49
Next Earnings
Mar 25, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding54,400,784
10 Day Avg. Volume1,151,884
30 Day Avg. Volume1,053,642
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)3.34
Price to Sales (P/S)21.82
P/FCF Ratio-11.70
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue114.27
Enterprise Value/Gross Profit-19.64
Enterprise Value/Ebitda-15.29
Forecast
1Y Price Target
$52.88Price Target Upside89.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.32
Revenue Forecast (FY)$138.40M
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst upgraded Capricor Therapeutics to a buy and raised the price target to $50, signaling increased confidence in deramiocel's commercial prospects and influencing investor sentiment.
Clinical Trial ResultsHOPE-3 pivotal trial met primary and key secondary endpoints and showed meaningful skeletal and cardiac benefits with a favorable safety profile, supporting deramiocel's therapeutic potential in Duchenne muscular dystrophy.
Valuation AdjustmentStrong HOPE-3 results prompted a lowered revenue risk adjustment and discount rate in valuation models, improving the company's fundamental valuation outlook and supporting a higher price target.
Bears Say
Market VolatilityShares could experience significant volatility as investors position for potential FDA flexibility around the totality of the data and await definitive regulatory feedback, raising downside risk for short-term holders.
Priority Review Voucher EligibilityEligibility for the Priority Review Voucher is uncertain because governing legislation may not be renewed, which could eliminate a projected source of non-dilutive cash and worsen the company's liquidity position.
Regulatory UncertaintyOutstanding questions about trial population composition, representation of background cardiac medications, manufacturing controls, and additional mechanism-of-action data could trigger further FDA inquiries or requirements and increase execution risk.
Capricor Therapeutics News
CAPR FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was $4.30 and its highest was $40.37 in the past 12 months.
What is Capricor Therapeutics’s market cap?
Capricor Therapeutics’s market cap is $1.52B.
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Mar 25, 2026 which is in 22 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.547 by $0.007.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -0.51.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 54,400,784 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.547. Following the earnings report the stock price went up 11.511%.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Currently, no hedge funds are holding shares in CAPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.88 (89.33% Upside)
$52.88 (89.33% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.22%
12-Months-Change
Fundamentals
Return on Equity
-107.79%
Trailing 12-Months
Asset Growth
36.03%
Trailing 12-Months
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
CAPR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in the clinical development of Daramycin and operational readiness for commercialization. However, financial challenges were evident with zero revenue in 2025 and increased operating expenses, alongside the need to address regulatory hurdles following a CRL.View all CAPR earnings summariesCAPR Stock 12 Month Forecast
Average Price Target
$52.88
▲(89.33% Upside)
Technical Analysis
Ownership Overview
1.08% Insiders
5.77% Mutual Funds
3.60% Other Institutional Investors
82.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---